主页 /
Products On Sale

Products On Sale

Quick View
PKI-587 ( Gedatolisib )

Catalog No. A11079
Quick View

添加到收藏
PI3K/mTOR 抑制剂

PKI-587 (Gedatolisib)是一种高效的PI3K/mTOR激酶抑制剂，可抑制PI3K-α，β，γ，δ亚型和mTOR，IC50分别为0.4、6.0、5.4、6.0和1.6 nM。了解更多

Bulk Inquiry Free Sample
Quick View
HS-173

Catalog No. A13021
Quick View

添加到收藏
PI3K 抑制剂

HS-173是一种新型磷脂酰肌醇3激酶（PI3K）抑制剂，通过促进细胞凋亡和抑制血管生成而具有抗肿瘤活性。了解更多

Product Citations (2)

Bulk Inquiry Free Sample
- Mostafa Khater, .et al. Gβγ translocation to the Golgi apparatus activates ARF1 to spatiotemporally regulate G protein-coupled receptor signaling to MAPK, J Biol Chem, 2021, Jan-Jun, 296:100805 PMID: 34022220
- Mostafa Khater, .et al. G protein βγ translocation to the Golgi apparatus activates MAPK via p110γ-p101 heterodimers, J Biol Chem, 2021, Jan 22;296:100325 PMID: 33493514
Quick View
CUDC-907 (Fimepinostat)

Catalog No. A11153
Quick View

添加到收藏
PI3K/HDAC 抑制剂

CUDC-907 (Fimepinostat)是针对PI3K和HDAC的单一小分子抑制剂，作用于PI3Kα和HDAC1/2/3/10，IC50分别为19 nM和1.7 nM/5 nM/1.8 nM/2.8 nM。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Chie Ishikawa, .et al. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia, Eur J Haematol, 2020, Eur J Haematol PMID: 32780889
Quick View
LY294002

Catalog No. A10547
Quick View

添加到收藏
PI3K 抑制剂

LY294002是PI3k抑制剂（IC50约为10μM）和酪蛋白激酶II抑制剂。了解更多

Product Citations (7)

Bulk Inquiry Free Sample
- Ming-Chun Hung, .et al. AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer, Cell Biosci, 2022, 12: 122 PMID: 35918763
- Chien-Feng Li, .et al. EMP2 induces cytostasis and apoptosis via the TGF β/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma, Cell Oncol (Dordr), 2021, Aug 2 PMID: 34339014
- Hiroharu Sakai, .et al. BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth, Exp Ther Med, 2021, March 5 PMID: 33747195
- Cheng Zhou, .et al. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia, Cell Death Dis, 2021, Mar 3;12(3):231 PMID: 33658491
- Daniel Limonta, .et al. Fibroblast growth factor 2 enhances Zika virus infection in human fetal brain, J Infect Dis, 2019, 2019 PMID: 30799482
- Lv H, .et al. CXCL8 gene silencing promotes neuroglial cells activation while inhibiting neuroinflammation through the PI3K/Akt/NF-κB-signaling pathway in mice with ischemic stroke, J Cell Physiol, 2018, Oct 26 PMID: 30362547
- Hui Liang, .et al. Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells, Sci Rep, 2017, 7: 40361 PMID: 28098170
Quick View
BYL719 (Alpelisib)

Catalog No. A11328
Quick View

添加到收藏
PI3K 抑制剂

BYL719 (Alpelisib)是一种口服生物可利用的磷脂酰肌醇3-激酶(PI3K)抑制剂，抑制 p110α/p110γ/p110δ/p110β 的 IC50 分别为 5 nM，250 nM，290 nM，1200 nM 。具有潜在的抗肿瘤活性。了解更多

Product Citations (3)

Bulk Inquiry Free Sample
- Lisann Pelzl, .et al. Antibody-mediated procoagulant platelet formation in COVID-19 is AKT dependent, J Thromb Haemost, 2022, Feb;20(2):387-398 PMID: 34752677
- J Wei, .et al. Profiling the surface proteome identifies actionable biology for TSC1 mutant cells beyond mTORC1 signaling, bioRxiv, 2018, 2018
- Pridham KJ, .et al. PIK3CB/p110β is a selective survival factor for glioblastoma, Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844